COVID-19 Clinical Trial Disruptions: A Real-World Test Of De-Centralized Techniques
Executive Summary
US FDA asks oncology drug sponsors for information on the impact of modifications to clinical trials during the pandemic – with close attention to remote monitoring and data collection.
You may also be interested in...
New Global Alliance To Drive Momentum On Decentralized Trials
A new multi-stakeholder alliance wants to improve the adoption of decentralized clinical trials that have already drawn much attention during the COVID-19 pandemic. There are plans to aggregate best practices, share evidence and information, and identify and address key barriers.
Informed Consent: For COVID-Affected Studies, A Handwritten Document May Suffice
Under certain circumstances, potential clinical trial participants may be able to provide informed consent by writing on a blank piece of paper that they voluntarily agree to participate in a given protocol and texting or emailing a photo of the signed document to the investigator, US FDA says in latest guidance update.
COVID-19 Trial Changes Are "Propulsive Force" For Digital Adoption
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.